

INDUSTRY-SPONSORED SYMPOSIUM

SATURDAY 6TH AUGUST 2022 AT 13:15 – 14:15

HALL C7, MESSE WIEN EXHIBITION & CONGRESS CENTER, VIENNA, AUSTRIA.

DECISIVE MOMENTS IN THE TREATMENT OF *MET* EXON 14 SKIPPING NSCLC

Faculty



Prof. Sanjay Popat (Chair)
The Royal Marsden Hospital and
The Institute of Cancer Research,
London, UK



Prof. Sonja Loges
University Medical Centre Mannheim,
University of Heidelberg, Germany



Prof. Paul Paik
Memorial Sloan Kettering Cancer
Center, New York, NY, USA



Prof. Enriqueta Felip
Vall d'Hebron University
Hospital, Barcelona, Spain

Agenda

A moment to welcome you

Take a moment to consider identification and treatment

Plenary session

A moment of clarity: Has our VISION¹ for *MET*ex14 skipping become a reality?

Plenary session

Seize the moment: The benefits of early treatment

Case study panel discussion

Make every moment matter: Optimising treatment

Case study panel discussion

A moment to reflect on *MET*ex14 skipping

Audience

Multidisciplinary team members with an interest in the management of patients with *MET*ex14 skipping NSCLC

Meeting Objectives

- To highlight the importance of testing for *MET*ex14 skipping in patients with NSCLC
- To examine recent evidence describing the efficacy and safety of tepotinib in this patient population
- To share practical insight into the management of these patients using case studies

This Industry-Sponsored Symposium is organized and sponsored by Merck Healthcare KGaA.

This program was approved by the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

In the European Economic Area (EEA), tepotinib as monotherapy is indicated for the treatment of adult patients with advanced NSCLC harbouring *MET* exon 14 skipping alterations, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. [Click here to view full Prescribing Information](#). For HCPs from other regions/countries, please check your locally approved Product Information.

© Merck Healthcare KGaA, Darmstadt, Germany. All rights reserved. June 2022. GL-TEP-00219.

Reference: 1. Paik PK et al. *N Engl J Med* 2020; 383:931–943.

